Ý nghĩa thực tiễn của phân loại glioma tích hợp theo phân loại khối u của Tổ chức Y tế Thế giới năm 2016

Ostrom, 2015, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012, Neuro-oncology, 17, iv1, 10.1093/neuonc/nov189

2007, WHO classification of tumours of the central nervous system, 8

van den Bent, 2010, Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective, Acta Neuropathol, 120, 297, 10.1007/s00401-010-0725-7

Pajtler, 2015, Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups, Cancer Cell, 27, 728, 10.1016/j.ccell.2015.04.002

Suzuki, 2015, Mutational landscape and clonal architecture in grade II and III gliomas, Nat Genet, 47, 458, 10.1038/ng.3273

Brat, 2015, Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas, N Engl J Med, 372, 2481, 10.1056/NEJMoa1402121

Ceccarelli, 2016, Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma, Cell, 164, 550, 10.1016/j.cell.2015.12.028

Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell, 155, 462, 10.1016/j.cell.2013.09.034

Sturm, 2012, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma, Cancer Cell, 22, 425, 10.1016/j.ccr.2012.08.024

Weller, 2015, Glioma, Nat Rev Dis Primers, 1, 15017, 10.1038/nrdp.2015.17

Bechet, 2014, Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas, Acta Neuropathol, 128, 733, 10.1007/s00401-014-1337-4

Capper, 2009, Monoclonal antibody specific for IDH1 R132H mutation, Acta Neuropathol, 118, 599, 10.1007/s00401-009-0595-z

Reuss, 2015, ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an ‘integrated’ diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma, Acta Neuropathol, 129, 133, 10.1007/s00401-014-1370-3

Ebrahimi, 2016, ATRX immunostaining predicts IDH and H3F3A status in gliomas, Acta Neuropathol Commun, 4, 60, 10.1186/s40478-016-0331-6

2016, WHO classification of tumours of the central nervous system, 10

Louis, 2014, International Society of Neuropathology-Haarlem Consensus Guidelines, for nervous system tumor classification and grading, Brain Pathol, 24, 429, 10.1111/bpa.12171

Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1

Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382

Yan, 2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med, 360, 765, 10.1056/NEJMoa0808710

Balss, 2008, Analysis of the IDH1 codon 132 mutation in brain tumors, Acta Neuropathol, 116, 597, 10.1007/s00401-008-0455-2

Sahm, 2014, Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma, Acta Neuropathol, 128, 551, 10.1007/s00401-014-1326-7

Hinrichs, 2016, Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups, Acta Neuropathol Commun, 4, 4, 10.1186/s40478-015-0270-7

Schwartzentruber, 2012, Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma, Nature, 482, 226, 10.1038/nature10833

Wu, 2012, Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and nonbrainstem glioblastomas, Nat Genet, 44, 251, 10.1038/ng.1102

Schindler, 2011, Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma, Acta Neuropathol, 121, 397, 10.1007/s00401-011-0802-6

Kleinschmidt-DeMasters, 2013, Epithelioid GBMs show a high percentage of BRAF V600E mutation, Am J Surg Pathol, 37, 685, 10.1097/PAS.0b013e31827f9c5e

Alexandrescu, 2016, Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas – same entity or first cousins?, Brain Pathol, 26, 215, 10.1111/bpa.12295

Parker, 2014, C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma, Nature, 506, 451, 10.1038/nature13109

Herrlinger, 2016, Gliomatosis cerebri: no evidence for a separate brain tumor entity, Acta Neuropathol, 131, 309, 10.1007/s00401-015-1495-z

Broniscer, 2016, Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas, Acta Neuropathol, 131, 299, 10.1007/s00401-015-1532-y

Tanboon, 2016, The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas, J Neuropathol Exp Neurol, 75, 4, 10.1093/jnen/nlv009

Hartmann, 2009, Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas, Acta Neuropathol, 118, 469, 10.1007/s00401-009-0561-9

Faulkner, 2014, EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers, Br J Neurosurg, 1, 23

Weller, 2014, Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy, Int J Cancer, 134, 2437, 10.1002/ijc.28576

Lewis, 2013, Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma, Science, 340, 857, 10.1126/science.1232245

Bender, 2013, Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas, Cancer Cell, 24, 660, 10.1016/j.ccr.2013.10.006

Capper, 2011, Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody, Acta Neuropathol, 122, 11, 10.1007/s00401-011-0841-z

Chen, 2014, Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma, Neuro Oncol, 16, 1478, 10.1093/neuonc/nou097

Masui, 2016, Molecular classification of gliomas, Handb Clin Neurol, 134, 97, 10.1016/B978-0-12-802997-8.00006-2

Appin, 2015, Biomarker-driven diagnosis of diffuse gliomas, Mol Aspects Med, 45, 87, 10.1016/j.mam.2015.05.002

Killela, 2013, TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal, Proc Natl Acad Sci U S A, 110, 6021, 10.1073/pnas.1303607110

Arita, 2013, Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss, Acta Neuropathol, 126, 267, 10.1007/s00401-013-1141-6

Jones, 2013, Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma, Nat Genet, 45, 927, 10.1038/ng.2682

Wick, 2014, MGMT testing: the challenges for biomarker-based glioma treatment, Nat Rev Neurol, 10, 372, 10.1038/nrneurol.2014.100

Mason, 2016, Glioblastoma in the elderly: making sense of the evidence, Neurooncol Pract, 3, 77

Perry, 2016, A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677), J Clin Oncol, 34

Dubbink, 2016, Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial, Neuro Oncol, 18, 388, 10.1093/neuonc/nov182

Nikiforova, 2016, Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors, Neuro Oncol, 18, 379, 10.1093/neuonc/nov289

Sahm, 2016, Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets, Acta Neuropathol, 131, 903, 10.1007/s00401-015-1519-8

Zacher, 2016, Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel, Brain Pathol

Wiestler, 2014, Assessing CpG island methylate phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial, Neuro Oncol, 16, 1630, 10.1093/neuonc/nou138

Hovestadt, 2013, Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays, Acta Neuropathol, 125, 913, 10.1007/s00401-013-1126-5